Skip to main content

Table 1 Characteristics of the study subjects

From: Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene

 

All

ABCG5/8 mutations

 

Variable

(n = 321)

YES (n = 26)

NO (n = 295)

p value

Age (years)

51 ± 18

52 ± 13

51 ± 16

n.s.

Gender (male/female)

172/142

12/14

160/135

n.s.

Hypertension

92 (29%)

7 (27%)

85 (29%)

n.s.

Diabetes

118 (37%)

9 (35%)

109 (37%)

n.s.

Smoking

70 (22%)

5 (19%)

65 (22%)

n.s.

Weighted polygenic score

0.53 ± 0.10

0.46 ± 0.11

0.54 ± 0.10

< 0.05

Baseline LDL-cholesterol (mg/dl)

192 ± 46

194 ± 56

191 ± 41

n.s.

LDL-cholesterol (mg/dl) under atorvastatin 10 mg/day

121 ± 48

121 ± 45

120 ± 34

n.s.

LDL-cholesterol (mg/dl) under atorvastatin 10 mg/day + ezetimibe 10 mg/day

83 ± 30

72 ± 26

87 ± 29

< 0.05

  1. ABCG5 ATP-binding cassette sub-family G member 5, ABCG8 ATP-binding cassette sub-family G member 8